Nurix Therapeutics Inc (NAS:NRIX)
$ 15.3408 -0.5592 (-3.52%) Market Cap: 941.97 Mil Enterprise Value: 756.14 Mil PE Ratio: 0 PB Ratio: 4.50 GF Score: 67/100

Nurix Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) - Panel Discussion Transcript

Feb 21, 2023 / 06:00PM GMT
Release Date Price: $9.03 (-7.10%)
Jim Birchenough
Wells Fargo - Analyst

Perfect. Well, I want to thank everyone for joining our TPD summit, and I want to thank Derek for organizing a great day. We've got a terrific panel scheduled next on the question of degradation versus inhibition, when does TPD makes sense and when doesn't it? And we've got a great group of panelists to anchor the discussion.

So, just going through the introductions of who is on the screen with me here. Gwenn Hansen is the Chief Science Officer of Nurix. She has been in that role since 2015. She had prior roles as VP of Research and VP of Drug Discovery. Also worked at Lexicon with Arthur Sands, prior to that has a postdoc from both MD Anderson and Baylor College of Medicine and started her career, maybe her PhD at Tennessee. So, a volunteer in the group.

Leah Fung is from Biotheryx. And she also serves as CSO. She's been in that role since 2014, prior role as VP of Med Chem. And she's had a variety of roles at Celgene and Signal and Houghton Pharma, really in the clinical chemistry and pharmacology area.

And then we've got Andy Combs

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot